ArticleBiomedical microdevices2026
Injectable, electrosprayed RGD-coupled alginate hydrogel microcapsules enable enhanced viability and sustained release of mesenchymal stem cells.
Article in Biomedical microdevices, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The clinical translation of mesenchymal stem cell (MSC) therapies remains limited due to rapid cell clearance and stress-induced viability loss during injection. These limitations emphasize the need to develop delivery systems allowing MSCs to persist in the tissue and exert their biological effect. Cell microencapsulation within alginate (Alg) biomaterials is a promising strategy, where arginine-glycine-aspartic acid (RGD)-coupled alginate (RAlg) hydrogels have recently demonstrated improved bioactivity. However, achieving precise encapsulation and injectability while preserving cell viability remains an ongoing challenge. This study presents an injectable delivery platform using electrosprayed RAlg microcapsules that enhance viability and sustain the release of MSCs. Electrospray parameters were optimized to yield a microcapsule size of 175.4 ± 21.1 μm with high uniformity and consistent spherical morphology. Electron microscopy images of the microcapsules revealed a highly ordered microporous architecture. Physicochemical characterization confirmed that the presence of RGD peptides did not significantly alter the swelling, viscoelasticity, and encapsulation efficiency of Alg. Successful encapsulation of MSCs were observed, with cells assuming a round morphology within the microcapsule. After 14 days, RAlg maintained significantly higher cell viability at 91.3% than Alg alone (84.9%). Furthermore, a time-dependent release of cells was observed, with intact microcapsules at day 1, partial degradation with 59-61% cell release at day 7, and extensive degradation with 78-81% release by day 14. Both RAlg and Alg had comparable release performance. Overall, this study demonstrates the potential of electrosprayed RAlg microcapsules as a biocompatible and injectable platform for the sustained delivery of viable MSCs in regenerative medicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.